3 Stocks Pushing The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 105 points (0.6%) at 16,554 as of Tuesday, April 22, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,226 issues advancing vs. 749 declining with 155 unchanged.

The Health Care sector currently sits up 2.7% versus the S&P 500, which is up 0.6%. Top gainers within the sector include Allergan ( AGN), up 15.7%, Intercept Pharmaceuticals ( ICPT), up 14.4%, Shire ( SHPG), up 5.7%, Valeant Pharmaceuticals International ( VRX), up 5.6% and Vertex Pharmaceuticals ( VRTX), up 4.6%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. AstraZeneca ( AZN) is one of the companies pushing the Health Care sector lower today. As of noon trading, AstraZeneca is down $2.30 (-3.3%) to $66.80 on heavy volume. Thus far, 5.4 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $66.55-$68.33 after having opened the day at $67.80 as compared to the previous trading day's close of $69.10.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $79.8 billion and is part of the drugs industry. Shares are up 16.4% year-to-date as of the close of trading on Monday. Currently there are 2 analysts that rate AstraZeneca a buy, 2 analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

CEOs Are Dropping Like Flies

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting